TR 3 Nodule Follow-Up
For a TR3 (low-suspicion) thyroid nodule, perform ultrasound surveillance at 1,3, and 5 years for nodules ≥1.5 cm; nodules <1.5 cm do not require routine biopsy or follow-up unless high-risk clinical features are present. 1
Risk Stratification and Initial Management
TR3 nodules carry a very low malignancy risk, with studies showing cancer rates of only 0.3-1.7% 2, 3, 4. The ACR TI-RADS system specifically addresses these low-suspicion nodules by establishing size-based thresholds that balance cancer detection against unnecessary interventions 5.
Size-Based Approach
- Nodules ≥1.5 cm: Recommend ultrasound follow-up at 1,3, and 5 years 1
- Nodules <1.5 cm: No routine biopsy or follow-up required unless clinical risk factors present 1, 2
The 1.5 cm threshold for TR3 nodules represents a critical decision point. Lowering this threshold to 1.0 cm would capture approximately 7 additional malignant nodules but would also add 118 benign nodules to surveillance protocols, substantially increasing healthcare burden without proportionate benefit 2.
Clinical Risk Factors That Modify Management
Even for nodules <1.5 cm, consider biopsy or closer surveillance if any of the following are present 1:
- History of head and neck irradiation
- Family history of thyroid cancer
- Suspicious palpation features (firm, fixed, rapidly growing)
- Presence of cervical adenopathy
- Age <15 years or male gender (higher baseline malignancy risk) 1
Surveillance Protocol Details
For TR3 nodules meeting size criteria for follow-up 1:
- Initial follow-up: 12 months after detection
- Second follow-up: 36 months (3 years)
- Final follow-up: 60 months (5 years)
- Imaging modality: Grayscale ultrasound of thyroid and central neck
What to Monitor
During surveillance, assess for 1:
- Size increase (particularly ≥20% increase in two dimensions with minimum 2 mm increase)
- Development of suspicious sonographic features (microcalcifications, irregular borders, marked hypoechogenicity)
- New cervical lymphadenopathy
When to Escalate to Biopsy
Perform fine-needle aspiration if during surveillance 1:
- Nodule develops multiple suspicious ultrasound features
- Significant size increase occurs
- Suspicious lymph nodes appear
- Patient develops new clinical risk factors
Important Caveats
The ACR TI-RADS approach is highly specific (98.8%) for identifying benign nodules 3, meaning very few cancers are missed. However, approximately 1.2% of TR2 and TR3 nodules <25 mm may harbor malignancy 3. These are predominantly micropapillary carcinomas (<1 cm) with excellent long-term prognosis 1, where active surveillance rather than immediate surgery has become an accepted management strategy 1.
For nodules exactly at borderline sizes (e.g., 14-15 mm), clinical judgment incorporating patient anxiety, ability to follow-up reliably, and presence of any clinical risk factors should guide whether to initiate surveillance 6.
Multinodular goiter: When multiple nodules are present, apply TR3 criteria to each nodule individually; biopsy only those meeting size and suspicion thresholds 1.
The conservative approach to TR3 nodules reflects the reality that most thyroid cancers detected are now micropapillary carcinomas with mortality rates remaining stable at 0.5 per 100,000 despite increasing incidence 1, supporting selective rather than aggressive intervention strategies.